<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29503" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Stimulants</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Faizy</surname>
            <given-names>Rubina M.</given-names>
          </name>
          <aff>KDHCD</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rubina Faizy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29503.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The term stimulants cover a broad class of drugs that increase the activity of the central nervous system. These drugs are used by a very high percentage of the general population for various reasons, including performance enhancement, medical benefits, and recreational purposes. Depending on the stimulant and jurisdiction, the drug may be legal or illegal. This activity outlines the indications, mechanisms of action, methods of administration, significant adverse effects, contraindications, and monitoring, of various substances that can be termed stimulants, so providers can direct patient therapy in using and counseling regarding their use, as part of the interprofessional team, with a basis on the current knowledge for optimal utilization.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the various mechanisms of the most commonly encountered stimulant agents.</p></list-item><list-item><p>Identify indications where stimulants are useful therapeutically.</p></list-item><list-item><p>Review the potential adverse events seen with various stimulants.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who need or might already be using stimulants.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29503&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29503">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29503.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The term stimulants cover a broad class of drugs that increase the activity of the central nervous system. These drugs are used by a very high percentage of the general population for various reasons, including performance enhancement, medical benefits, and recreational purposes. The drug may be legal or illegal, depending on the stimulant and jurisdiction.</p>
        <p>Caffeine is the most commonly used stimulant in the world, used for a combination of dietary and recreational purposes as well as performance enhancement. Other legal stimulants are generally used for performance enhancement but may also find utility for specific symptoms depending on the drug. Illegal and/or prescription stimulants carry medical purposes but are also heavily used for recreational reasons.<xref ref-type="bibr" rid="article-29503.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Medical Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Attention deficit hyperactivity disorder (ADHD)</p>
          </list-item>
          <list-item>
            <p>Narcolepsy</p>
          </list-item>
          <list-item>
            <p>Asthma</p>
          </list-item>
          <list-item>
            <p>Obesity</p>
          </list-item>
          <list-item>
            <p>Nasal and sinus congestion</p>
          </list-item>
          <list-item>
            <p>Hypotension due to anesthesia</p>
          </list-item>
        </list>
        <p>As the most commonly used stimulant, caffeine is found in various drinks and foods such as tea, coffee, and chocolate. It is consumed habitually in many countries worldwide, given its mild to moderate stimulant effects, which promote alertness. Its general properties have also made it rampant among students and athletes who seek a cognitive or physical edge, respectively.&#x000a0;&#x000a0;</p>
        <p>The amphetamine class of drugs is used for medical and recreational purposes. They carry a multitude of effects that include general and cognitive performance enhancement along with euphoric effects. They also induce aphrodisiac effects in many users. ADHD treatment commonly uses a combination of dextroamphetamine and levoamphetamine, as well as pure dextroamphetamine and lisdexamfetamine. Methamphetamine is a widely trafficked and illegal drug used for recreational purposes. Athletes use many medications related to the amphetamine class of drugs for physical performance enhancement. These drugs fall under bans by the world anti-doping agency (WADA).<xref ref-type="bibr" rid="article-29503.r2">[2]</xref>&#x000a0;</p>
        <p>The purpose of this article is to review the most commonly used stimulants, their indications, and possible short-term and long-term adverse effects.&#x000a0; &#x000a0; &#x000a0;</p>
      </sec>
      <sec id="article-29503.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The general mechanism of stimulants revolves around increased catecholamine levels and increased agonistic activity at adrenergic receptors.&#x000a0;</p>
        <p>
<bold>Caffeine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Caffeine has a unique mechanism as a stimulant as it works as an inhibitor at the adenosine receptors. Agonism at these receptors induces a sensation of drowsiness, and therefore inhibition at these receptors leads to increased energy levels.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Caffeine also increases intraocular pressure in those affected with glaucoma.<xref ref-type="bibr" rid="article-29503.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Amphetamines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The general mechanism of action of amphetamines is the induction of catecholamines, specifically norepinephrine and dopamine. These catecholamines lead to increased energy levels, euphoria, increased libido, and higher cognition.<xref ref-type="bibr" rid="article-29503.r4">[4]</xref>&#x000a0;This class also includes non-therapeutic agents such as 3,4-methylenedioxymethamphetamine (MDMA, aka ecstasy),&#x000a0;methylenedioxypyrovalerone (MDPV), and mephedrone.<xref ref-type="bibr" rid="article-29503.r5">[5]</xref><xref ref-type="bibr" rid="article-29503.r6">[6]</xref><xref ref-type="bibr" rid="article-29503.r7">[7]</xref><xref ref-type="bibr" rid="article-29503.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Methylphenidate</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>This drug blocks the dopamine transporter (DAT) and the norepinephrine transporter (NET), leading to increased dopamine and norepinephrine levels with the inhibition of their reuptake.<xref ref-type="bibr" rid="article-29503.r8">[8]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Ephedrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The primary mechanism of ephedrine is increased norepinephrine activity at the adrenergic receptors. Pseudoephedrine specifically works also as a nasal and sinus decongestant.<xref ref-type="bibr" rid="article-29503.r9">[9]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Cocaine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The induction of most of the effects of cocaine is through the blockade of the dopamine transporter protein. This results in increased dopamine levels at the synaptic cleft, and hence the effects of dopamine become amplified.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Pseudoephedrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pseudoephedrine is a drug used as a nasal decongestant and stimulant.<xref ref-type="bibr" rid="article-29503.r10">[10]</xref> It is a sympathomimetic agent that belongs to the amphetamine and phenethylamine drug classes. It appears in a number of over-the-counter formulations, including combinations with guaifenesin, antihistamines, acetaminophen, and dextromethorphan.</p>
          </list-item>
        </list>
        <p>
<bold>Khat (<italic toggle="yes">Catha edulis</italic>)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Khat is a flowering plant indigenous to the Arabian Peninsula and the Horn of Africa.<xref ref-type="bibr" rid="article-29503.r11">[11]</xref>&#x000a0;It contains a substance called cathinone, and the World Health Organization considers it a potential drug of abuse, although they do not rate it as a serious addiction risk. It is a keto-amphetamine and is banned in the USA.</p>
          </list-item>
        </list>
        <p>
<bold>Modafinil</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>This is a CNS-stimulating agent used to treat sleepiness related to obstructive sleep apnea, narcolepsy, and shift-worker disorder. It is a weak dopamine uptake inhibitor, although the precise mechanism for its stimulating effects remains unknown.</p>
          </list-item>
        </list>
        <p>Additional stimulants are available, especially in pre-workout supplements, which have direct agonistic effects on adrenergic receptors. Examples include synephrine, which is present in many supplements, and methylsynephrine, which the WADA banned. Other known stimulants, such as 1,3-dimethlamylamine (DMAA), have lesser-known pharmacologic mechanisms.<xref ref-type="bibr" rid="article-29503.r12">[12]</xref><xref ref-type="bibr" rid="article-29503.r13">[13]</xref></p>
      </sec>
      <sec id="article-29503.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The primary method of administration for stimulants is oral intake. Recreational administration of stimulants also occurs by intramuscular and/or intravascular injection, smoking, and intranasal administration; this will vary by individual agent.</p>
      </sec>
      <sec id="article-29503.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Stimulants can induce a broad range of short-term and long-term adverse effects. The side effect profile is dependent on numerous variables. The major factors that influence adverse effect outcomes are the user's body weight, the specific stimulant used, the dose of the agent taken, and tolerance. Other factors include the use of other drugs and stimulants and oral intake on an empty stomach. The adverse effects of stimulants include the following<xref ref-type="bibr" rid="article-29503.r14">[14]</xref><xref ref-type="bibr" rid="article-29503.r15">[15]</xref><xref ref-type="bibr" rid="article-29503.r16">[16]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Decreased appetite - possible therapeutic effect in specific users</p>
          </list-item>
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Jitteriness</p>
          </list-item>
          <list-item>
            <p>Headaches</p>
          </list-item>
          <list-item>
            <p>Weight loss</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Pruritus</p>
          </list-item>
          <list-item>
            <p>Paranoia</p>
          </list-item>
          <list-item>
            <p>Sweating</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
          <list-item>
            <p>Shortness of breath</p>
          </list-item>
          <list-item>
            <p>Chest pain</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
          <list-item>
            <p>EKG abnormalities: inappropriate sinus tachycardia, sinus arrhythmia, prolonged QT, premature ventricular contractions, ventricular tachycardia</p>
          </list-item>
          <list-item>
            <p>Cerebrovascular event</p>
          </list-item>
          <list-item>
            <p>Sudden cardiac death</p>
          </list-item>
        </list>
        <p>The above list is general and depends on a number of factors, including the specific agent, mode of administration, and the underlying health&#x000a0;and comorbidities of the person using the drug.<xref ref-type="bibr" rid="article-29503.r14">[14]</xref><xref ref-type="bibr" rid="article-29503.r15">[15]</xref><xref ref-type="bibr" rid="article-29503.r16">[16]</xref></p>
        <p>If intranasal administration occurs, particularly with cocaine, there is a risk of nose bleeds and significant rhinorrhea.&#x000a0;</p>
        <p>Other long-term adverse effects from stimulant use involve increased risks of strokes and myocardial infarctions. The reasoning behind the elevated risks appears to be multifactorial and primarily due to the cardiovascular effects of stimulants.</p>
      </sec>
      <sec id="article-29503.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are numerous relative contraindications to the use of stimulants. Patients with advanced arteriosclerosis should use minimal stimulants given the elevated risk of myocardial infarction, as stimulants elevate cardiac demand. Also, patients with severe hypertension will exacerbate their existing elevated high blood pressure when using stimulants and, therefore, should minimize their use. Untreated hyperthyroidism, glaucoma, and a recent stroke are also relative contraindications to stimulant use. Cardiac arrhythmias are also known to worsen and even result from certain stimulants; therefore,&#x000a0;individuals so affected should avoid stimulant use.<xref ref-type="bibr" rid="article-29503.r17">[17]</xref></p>
        <p>Younger patients under the age of 12 and pregnant patients should avoid using stimulants. From a general perspective, some patients are susceptible to stimulants and should either avoid using or minimize their dose.</p>
      </sec>
      <sec id="article-29503.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is prudent for the clinician considering stimulant therapy for any condition for which it is indicated to perform a careful assessment of the patient by using a targeted cardiac history (eg, patient history of previously detected cardiac disease, palpitations, syncope, or seizures; a family history of sudden death in children or young adults; hypertrophic cardiomyopathy; long QT syndrome) and a physical examination, including a careful cardiac examination. This approach is appropriate for adults and children.<xref ref-type="bibr" rid="article-29503.r18">[18]</xref><xref ref-type="bibr" rid="article-29503.r19">[19]</xref></p>
      </sec>
      <sec id="article-29503.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Treatment of a stimulant overdose depends on the specific agent used, the ongoing adverse effects, and the potential risk for further adverse effects. The generally available options for treating stimulant toxicity are benzodiazepines, beta-blockers, antiarrhythmic agents, and antihypertensive medications. Certain medications under these classes of drugs may be contraindicated depending on the specific drug used. Benzodiazepines lower the associated anxiety of stimulant toxicity and may improve the patient's vital signs. They are also the primary option if the patient is experiencing seizures. Beta-blockers are useful for lowering the patient's heart rate, given that tachycardia is a very common symptom of stimulant overdose. As well, they can improve the patient's hypertensive state. Antiarrhythmic medications are generally reserved for ventricular arrhythmias that result from stimulant toxicity.<xref ref-type="bibr" rid="article-29503.r20">[20]</xref></p>
        <p>It is critical to confirm the specific drug that induces the stimulant toxicity given the potential treatment contraindications. For example, cocaine overdoses are a frequent cause of stimulant toxicity. While they induce tachycardia, chest pain, and hypertension, the use of beta-blockers may potentially be cardiotoxic to a patient who has overdosed on cocaine.<xref ref-type="bibr" rid="article-29503.r21">[21]</xref></p>
      </sec>
      <sec id="article-29503.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Stimulants make up a broad range of drugs; many find a use for recreational and performance enhancement reasons. Primary care&#x000a0;clinicians (including MDs, DOs, NPOs, and PAs) can significantly improve healthcare outcomes by educating their patients on the short-term and long-term effects of stimulant use. While caffeine is a relatively safe stimulant, other stimulants used by athletes, students, and recreational users can pose a significant health threat. It is essential not to overlook them in the patient's social history gathering process. Furthermore, pharmacists are readily accessible by patients and hence can carry out a critical role in educating the public; this is especially true on pre-workout supplements containing various stimulants. When a patient is prescribed a stimulant, the pharmacist can verify that no drug-drug interactions exist that can lead to an adverse event. This again emphasizes the point already made about collecting an accurate patient social and medication/supplement history.</p>
        <p>Monitoring patient stimulant usage is not confined to illicit, recreational, or non-prescribed use of these agents. When prescribing stimulant medications for legitimate purposes (ADHD, narcolepsy, etc.), the onus remains on the entire interprofessional team to monitor the patient's progress and condition and openly share information among all interprofessional team members. All healthcare team members, including clinicians, nurses, and pharmacists, must coordinate their activities and exercise open communication to help patients not misuse stimulant drugs. [Level 5]</p>
      </sec>
      <sec id="article-29503.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29503&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29503">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29503/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29503">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29503.s11">
        <title>References</title>
        <ref id="article-29503.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornelis</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>The Impact of Caffeine and Coffee on Human Health.</article-title>
            <source>Nutrients</source>
            <year>2019</year>
            <month>Feb</month>
            <day>16</day>
            <volume>11</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30781466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heal</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gosden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nutt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Amphetamine, past and present--a pharmacological and clinical perspective.</article-title>
            <source>J Psychopharmacol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>479</fpage>
            <page-range>479-96</page-range>
            <pub-id pub-id-type="pmid">23539642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nehlig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daval</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Debry</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects.</article-title>
            <source>Brain Res Brain Res Rev</source>
            <year>1992</year>
            <season>May-Aug</season>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-70</page-range>
            <pub-id pub-id-type="pmid">1356551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calipari</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Amphetamine mechanisms and actions at the dopamine terminal revisited.</article-title>
            <source>J Neurosci</source>
            <year>2013</year>
            <month>May</month>
            <day>22</day>
            <volume>33</volume>
            <issue>21</issue>
            <fpage>8923</fpage>
            <page-range>8923-5</page-range>
            <pub-id pub-id-type="pmid">23699503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>3,4-methylenedioxymethamphetamine (MDMA): current perspectives.</article-title>
            <source>Subst Abuse Rehabil</source>
            <year>2013</year>
            <volume>4</volume>
            <fpage>83</fpage>
            <page-range>83-99</page-range>
            <pub-id pub-id-type="pmid">24648791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nutt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Saulsbury</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Blakemore</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Development of a rational scale to assess the harm of drugs of potential misuse.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>Mar</month>
            <day>24</day>
            <volume>369</volume>
            <issue>9566</issue>
            <fpage>1047</fpage>
            <page-range>1047-53</page-range>
            <pub-id pub-id-type="pmid">17382831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Docherty</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Alsufyani</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of Drugs Used as Stimulants.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>61 Suppl 2</volume>
            <fpage>S53</fpage>
            <page-range>S53-S69</page-range>
            <pub-id pub-id-type="pmid">34396557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volkow</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gatley</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of methylphenidate: insights from PET imaging studies.</article-title>
            <source>J Atten Disord</source>
            <year>2002</year>
            <volume>6 Suppl 1</volume>
            <fpage>S31</fpage>
            <page-range>S31-43</page-range>
            <pub-id pub-id-type="pmid">12685517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Persky</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Modelling the cardiovascular effects of ephedrine.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2004</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>552</fpage>
            <page-range>552-62</page-range>
            <pub-id pub-id-type="pmid">15089807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trinh</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ritsma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effect of pseudoephedrine in sport: a systematic review.</article-title>
            <source>BMJ Open Sport Exerc Med</source>
            <year>2015</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>e000066</fpage>
            <pub-id pub-id-type="pmid">27900142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiidow</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Minhat</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Zulkefli</surname>
                <given-names>NAM</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A systematic review on risk factors for khat chewing among adolescents in the African continent and Arabian Peninsula.</article-title>
            <source>PLoS One</source>
            <year>2022</year>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>e0263372</fpage>
            <pub-id pub-id-type="pmid">35113927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Geranium</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>6</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30000892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kidron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lakhkar</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <chapter-title>Adrenergic Drugs</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">30480963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruening</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohrt</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Exploring weight control as motivation for illicit stimulant use.</article-title>
            <source>Eat Behav</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>30</volume>
            <fpage>72</fpage>
            <page-range>72-75</page-range>
            <pub-id pub-id-type="pmid">29886378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tivakaran</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <chapter-title>QT Prolonging Drugs</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">30521285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <chapter-title>Premature Ventricular Contraction</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30422584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fairman</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Peckham</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sclar</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?</article-title>
            <source>Drugs Real World Outcomes</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-79</page-range>
            <pub-id pub-id-type="pmid">29305714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pliszka</surname>
                <given-names>S</given-names>
              </name>
              <collab>AACAP Work Group on Quality Issues</collab>
            </person-group>
            <article-title>Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>894</fpage>
            <page-range>894-921</page-range>
            <pub-id pub-id-type="pmid">17581453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fayyad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Graaf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Angermeyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demyttenaere</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>De Girolamo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Lara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>L&#x000e9;pine</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ormel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Posada-Villa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zaslavsky</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder.</article-title>
            <source>Br J Psychiatry</source>
            <year>2007</year>
            <month>May</month>
            <volume>190</volume>
            <fpage>402</fpage>
            <page-range>402-9</page-range>
            <pub-id pub-id-type="pmid">17470954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suen</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Davy-Mendez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>LeSaint</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Coffin</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>Emergency department visits and trends related to cocaine, psychostimulants, and opioids in the United States, 2008-2018.</article-title>
            <source>BMC Emerg Med</source>
            <year>2022</year>
            <month>Feb</month>
            <day>04</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">35120449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29503.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lo</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Virk</surname>
                <given-names>HUH</given-names>
              </name>
              <name>
                <surname>Lakhter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gongora</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pressman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Figueredo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis.</article-title>
            <source>Am J Med</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>132</volume>
            <issue>4</issue>
            <fpage>505</fpage>
            <page-range>505-509</page-range>
            <pub-id pub-id-type="pmid">30562494</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
